What Is Longevity Science? A Plain-Language Guide to the Fastest-Growing Field in US Health Research
20 September 2026 · 7 min read
Searches for longevity science have grown sharply in the United States, yet the term is still widely misunderstood. This guide explains what the field actually studies, how it differs from anti-ageing marketing, and why credible researchers treat ageing as a biological process that can be measured and, in part, modified.
A working definition
Longevity science is the study of the biological mechanisms that drive ageing, and of interventions that may extend the years lived in good health, often called healthspan. It is not about immortality, and it is not the same as the anti-ageing industry. The field's serious core is geroscience, the discipline that asks why ageing is the largest shared risk factor for cancer, cardiovascular disease, dementia and most other chronic conditions.
The organising idea is straightforward. If ageing biology can be slowed or modified, many diseases could be delayed at once, rather than treated one by one. That hypothesis now shapes research programmes at the US National Institute on Aging, major universities and a growing number of biotechnology companies.
What researchers actually study
Most programmes are organised around the hallmarks of ageing, a framework first proposed in 2013 and expanded in 2023 in the journal Cell. The hallmarks include genomic instability, cellular senescence, mitochondrial dysfunction, chronic inflammation and altered nutrient sensing, among others. They give the field a shared vocabulary, so results from different laboratories can be compared.
Practical work falls into a few broad streams. Some groups study pathways such as mTOR and AMPK that regulate how cells respond to nutrients and stress. Others develop senolytic compounds that clear damaged senescent cells in animal models. A third stream builds biomarkers of ageing, measurable indicators intended to show whether an intervention is changing biological age, not just symptoms.
What is established and what is not
Established: ageing is malleable in model organisms, exercise and cardiometabolic health strongly influence healthspan in humans, and several drugs approved for other uses are being formally tested against ageing-related outcomes. The TAME trial, led from the United States, is testing whether metformin can delay the onset of multiple age-related diseases, a landmark design for the field.
Not established: no therapy is approved anywhere to treat ageing itself, claims of reversing ageing in humans remain unproven, and most consumer longevity products lack controlled human evidence. Responsible sources, including the National Institute on Aging, are explicit about this boundary. Anyone claiming otherwise should be read with caution.
Why the United States leads
The US combines the largest concentration of ageing research funding, the National Institute on Aging's budget, deep venture capital interest and a large consumer market searching for answers. That mix produces both world-class science and aggressive marketing, which is exactly why a clear-eyed definition of the field matters.
For MR Longevity, the mission is to connect the credible side of this landscape, researchers, clinicians, investors and members of the public, so that promising science reaches people responsibly. Explore our missions and the UK longevity directory to see how that work is organised.
- National Institute on Aging
- Hallmarks of Aging: An Expanding Universe, Cell (2023)
- TAME Trial, American Federation for Aging Research
This article is for general information only and is not medical advice. Decisions about your health should be made with a qualified clinician.